Previous 10 | Next 10 |
LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients sufferi...
VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Quark Venture LP (Quark) and GF Securities are pleased to announce the successful listing of portfolio company, SQZ Biotechnologies (NYSE: SQZ) (“SQZ”) on the New York Stock Exchange (NYSE) as of Octobe...
LEXINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...
OraSure receives emergency use authorization for OMNIgene. Keros Therapeutics initiates Phase 2 clinical trial for Myelodysplastic Syndromes. Affimed to collaborate with NKMax America for SNK01 natural killer cell therapy. For further details see: OraSure's Emergency Use...
Keros Therapeutics ([[KROS]] +5.9%) has dosed the first two participants in a Phase 2 clinical trial evaluating KER-050 for the treatment of anemia and thrombocytopenia in myelodysplastic syndromes ((MDS)).Keros presented data from its Phase 1 clinical trial of KER-050 in healthy post-me...
First two participants dosed in a Phase 2 clinical trial of KER-050 in MDS Initial data expected by mid-2021 LEXINGTON, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS)...
Following an active September, two IPOs are scheduled to raise $200 million in the week ahead. Several companies could join the IPO calendar early in the week, such as Spruce Biosciences, Shattuck Labs, and Kronos Bio. Live TV streaming platform fuboTV plans to raise $150 million ...
LEXINGTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musc...
LEXINGTON, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffer...
Keros Therapeutics (NASDAQ: KROS ) : Q2 GAAP EPS of -$0.62 beats by $0.06 . cash and cash equivalents of $144.7M. Press Release More news on: Keros Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
News, Short Squeeze, Breakout and More Instantly...
Keros Therapeutics Inc. Company Name:
KROS Stock Symbol:
NASDAQ Market:
Keros Therapeutics Inc. Website:
2024-06-25 22:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-24 17:15:02 ET Oppenheimer analyst issues OUTPERFORM recommendation for KROS on June 24, 2024 04:14PM ET. KROS was trading at $46.48 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recomme...
LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patie...